Virtual Symposium Agenda


Agenda subject to change.

Sunday, April 5, 2020

8:00 am

Poster viewing opens


11:00 am

Opening Remarks

Jonathan Silverberg, MD, PhD, MPH


11:10 am

Mini-Symposium 1: Evaluation of the Burden and Comorbidities of Atopic Dermatitis

  • 11:10 am

    What’s New in the Pathogenesis of Atopic Dermatitis
    Mark Boguniewicz, MD
  • 11:40 am

    Atopic Dermatitis: When to Suspect Systemic Disease or Alternate Diagnoses
    Jonathan I Silverberg, MD, PhD, MPH
  • 12:10 pm

    Assessing Severity and Burden of Atopic Dermatitis in Clinical Trials and Practice
    Eric Simpson, MD, MCR
  • 12:40 pm

    Atopic Comorbidities of Atopic Dermatitis
    Mark Boguniewicz, MD
  • 1:10 pm

    Non-atopic Comorbidities of Atopic Dermatitis
    Jonathan I Silverberg, MD, PhD, MPH

1:38 pm

Late-breaking research

  • 1:38 pm

    Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis
    Amy Paller, MD, MS
  • 1:51 pm

    What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis? A prospective clinical study
    Jonathan I Silverberg, MD, PhD, MPH
  • 2:04 pm

    Association and Impact of Atopic Dermatitis Out-Of-Pocket Healthcare Expenses with Disease Severity and Control
    Wendy Smith Begolka, MBS
  • 2:17 pm

    Atopic Dermatitis Search Strategy Variation Among Systematic Reviews
    Marissa Ayasse
  • 2:30 pm

    What Patient-Centric Research Has Taught Us About Atopic Dermatitis
    Korey Capozza, MPH

2:30 pm

What Patient-Centric Research Has Taught Us About Atopic Dermatitis

Korey Capozza, MPH


3:00 pm

Mini-Symposium 2: Current and Emerging Therapies for Atopic Dermatitis

  • 3:00 pm

    Current Systemic and Biologic Treatment of Atopic Dermatitis
    Jonathan I Silverberg, MD, PhD, MPH
  • 3:30 pm

    Emerging Therapies in Atopic Dermatitis
    Amy S Paller, MD, MS

3:56 pm

Late-breaking research

  • 3:56 pm

    Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
    Kim A. Papp, MD, PhD, FRCPC
  • 4:09 pm

    Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Phase 3 JADE MONO-2 Study
    Melinda Gooderham, MSc, MD, FRCPC
  • 4:22 pm

    Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: Results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5)
    Eric Simpson, MD, MCR
  • 4:35 pm

    Long-Term Efficacy and Safety of Dupilumab in Adolescents With Atopic Dermatitis: Results From an Open-Label Extension Trial (LIBERTY AD PED-OLE)
    Andrew Blauvelt, MD, MBA
  • 4:48 pm

    Dupilumab Significantly Improves Atopic Dermatitis in Children Aged ≥6 to <12 years: Results From Phase 3 Trial (LIBERTY AD PEDS)
    Amy Paller, MD, MS

5:00 pm

Closing Remarks

Jonathan Silverberg, MD, PhD, MPH

Sponsored by an unrestricted educational grant from Incyte.
© 2020 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.